Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma
Sponsor: Janssen Research & Development, LLC
Summary
The purpose of this pre-approval access program is to provide talquetamab for the treatment of participants with relapsed or refractory multiple myeloma.
Official title: 64407564MMY4002: PRE-APPROVAL ACCESS Single Patient Request (SPR) TREATMENT GUIDELINE for TALQUETAMAB for Treating Physician Use in Relapsed and Refractory Multiple Myeloma Concurrent With Relapsed and Refractory Light Chain (AL) Amyloidosis
Key Details
Gender
Not specified
Age Range
18 Years - Any
Study Type
EXPANDED_ACCESS
Enrollment
Not specified
Start Date
Not specified
Completion Date
Not specified
Last Updated
2026-10-06
Healthy Volunteers
Not specified
Conditions
Interventions
Talquetamab
Talquetamab will be administered subcutaneously (SC).